Background/Aims: Several inflammatory biomarkers have been found to be associated with cardiovascular disease or all-cause mortality in dialysis patients, but their usefulness in clinical practice or as surrogate endpoints is not certain. The purpose of the present study was to determine the intrapatient variation of C-reactive protein, IL-6, fetuin-A and albumin in a population of dialysis patients. Methods: Apparently healthy dialysis patients with either a tunneled dialysis catheter or fistula had monthly assessments of these biomarkers for a total of four determinations, and the intraclass correlation coefficients were calculated as measures of intersubject variance. Results: Our results showed large within-subject variation relative to the total variation in the measurements (31–46%). Having a tunneled catheter as opposed to a fistula was not significantly associated with mean levels, suggesting that chronic subclinical catheter infection does not explain the variation seen in the biomarkers. In contrast, there was a rapid change in these biomarkers with a clinically apparent acute infection. Conclusion: These results suggest that these biomarkers have limitations for use as surrogate endpoints in clinical trials due to wide fluctuations, even in apparently clinically healthy individuals.

Keywords:
Biomarkers, precision, Chronic inflammation, Chronic kidney disease, CKD stage 5D, Inflammatory biomarkers, intrapatient variance, Tunneled dialysis catheter
1.
Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363–369.
2.
Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, et al: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899–1911.
3.
Moe SM, Chen NX: Inflammation and vascular calcification. Blood Purif 2005;23:64–71.
4.
Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458–482.
5.
Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469–476.
6.
Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, et al: Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6? Kidney Int Suppl 2002:103–108.
7.
Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, et al: Association of low fetuin-A concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827–833.
8.
Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524–1538.
9.
Stenvinkel P: Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant 2002;17(suppl 8):33–40.
10.
Franek E, Blaschyk R, Kolonko A, Mazur-Psonka L, et al: Chronic periodontitis in hemodialysis patients with chronic kidney disease is associated with elevated serum C-reactive protein concentration and greater intima-media thickness of the carotid artery. J Nephrol 2006;19:346–351.
11.
Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89–95.
12.
Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–843.
13.
Ketteler M, Wanner C, Metzger T, Bongartz P, et al: Deficiencies of calcium-regulatory proteins in dialysis patients: a novel concept of cardiovascular calcification in uremia. Kidney Int Suppl 2003:S84–S87.
14.
Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003;111:1805–1812.
15.
Tsirpanlis G, Bagos P, Ioannou D, Bleta A, et al: The variability and accurate assessment of microinflammation in haemodialysis patients. Nephrol Dial Transplant 2004;19:150–157.
16.
De Maat MP, de Bart AC, Hennis BC, Meijer P, et al: Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996;16:1156–1162.
17.
Van Tellingen A, Grooteman MP, Schoorl M, Bartels PC, et al: Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int 2002;62:632–638.
18.
Souberbielle JC, Boutten A, Carlier MC, Chevenne D, et al: Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006;70:345–350.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.